Hepatocellular Carcinoma
Conditions
Keywords
Hepatic Arterial Infusional Chemotherapy, Lipiodol Embolization, Hepatocellular carcinoma
Brief summary
Hepatic artery infusion chemotherapy (HAIC) is a locoregional therapy commonly used in hepatocellular carcinoma (HCC), with high response rates and minimal impairment of liver function reported. Transarterial chemoembolization (TACE) and transarterial embolization (TAE) are also commonly used in HCC, with high response rates reported yet carry risks of impairing liver function after repeated embolization with a definitive embolic agent. On the other hand, lipiodol used in TACE/TAE has transient and plastic embolization effects on the tumor in contrast to the long-lasting embolization effect of the definitive embolic agent. This study investigates whether combining HAIC with lipiodol embolization will increase efficacy with good liver function preservation.
Detailed description
Hepatic artery infusion chemotherapy (HAIC) is an effective locoregional therapy commonly utilized in hepatocellular carcinoma (HCC). The rationale for the anti-tumor efficacy of HAIC is to deliver high local concentrations of chemotherapeutic agents to the liver tumor. Previous studies on HAIC alone or in combination with other systemic therapies have demonstrated excellent intrahepatic tumor contr rates and survival benefits. The investigators have previously conducted a pilot study of HAIC in National Taiwan University Hospital (NTUH) using cisplatin and 5-fluorouracil and demonstrated a high response rate of 26% in advanced HCC patients. In addition to the observed efficacy, HAIC does not impair liver function significantly over repeated administration and can be safely given to patients with poor or limited liver reserve. Transarterial chemoembolization (TACE) and transarterial embolization (TAE) are the most recognized standard treatment in intermediate-stage HCC and are also commonly utilized in advanced-stage HCC. TACE procedure is based on administering a cytotoxic drug mixed with lipiodol followed by definitive embolization of the tumor-feeding arteries by an embolic agent. However, repeated embolization can impair liver function and jeopardize the chance of patients receiving further salvage treatment. Lipiodol used in TACE/TAE has transient and plastic embolization effects on the tumor in contrast to the long-lasting embolization effect of the embolic agent, such as Gelfoam. Performing embolization with lipiodol alone without an embolic agent may limit detrimental effects on the normal liver and help preserve liver function in patients with HCC. The investigators hypothesize that combining HAIC and transient embolization using lipiodol may have enhanced efficacy compared to HAIC alone. In addition, the unwanted liver function impairment caused by repeated embolization is alleviated by the characteristic transient embolization effect of lipiodol. Thus, The investigators propose this prospective, single-arm, phase 2 pilot study comprising HAIC with cisplatin and 5-fluorouracil in combination with lipiodol embolization to investigate its efficacy and safety in patients with advanced HCC.
Interventions
DRUGCisplatin
Chemotherapy regimen • Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity
DRUG5-fluorouracil
Chemotherapy regimen • Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity
PROCEDURELipiodol embolization
Lipiodol embolization protocol * Lipiodol embolization will be performed on day 3 after completion of 5-FU infusion, up to 4 cycles. Fixed dose lipiodol of 10mL will be given on day 3 followed by 30mL normal saline flush. * The administration of lipiodol is mandatory on cycle 1. The administration of lipiodol on cycle 2 to cycle 4 will depend on the discretion of the treating physician and the presence of adverse effects from lipiodol embolization.
Sponsors
National Taiwan University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF). 2. Histologically or clinically (typical HCC imaging findings by multi-phase CT or MRI) diagnosed HCC. 3. Barcelona Clinic Liver Cancer (BCLC) Stage C disease (liver confined disease or liver predominant disease, as determined by the investigator) or BCLC Stage B disease who failed standard treatment (i.e., TACE in intermediate stage HCC or systemic therapy in advanced HCC) or refused standard treatment or intolerable to standard treatment. 4. Archival tissue available (\< 2 years) or agree to have biopsy tissue at baseline 5. Age \> 20 years at the time of study entry. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 7. Child-Pugh class A or B7 8. ≥1 measurable lesion per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 in the liver 9. Body weight \>30 kg 10. Adequate normal organ and marrow function as defined below: (1) Hemoglobin ≥9.0 g/dL (2) Absolute neutrophil count (ANC) ≥1.0 x 109/L (≥ 1,000 per mm3) (3) Platelet count ≥75 x 109/L (≥75,000 per mm3) (4) Serum bilirubin ≤2 x institutional upper limit of normal (ULN). (5) AST (SGOT)/ALT (SGPT) ≤3x institutional upper limit of normal unless active liver malignancies are present, in which case it must be ≤5x ULN (6) Measured creatinine clearance (CL) \>40 mL/min or Calculated creatinine CL\>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance: 11. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. 12\. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. 13\. Must have a life expectancy of at least 12 weeks
Exclusion criteria
1. Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma 2. The result of lung perfusion scan of the HAIC port \> 30% 3. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study 4. Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies) ≤14 days prior to the first dose of the study drug. If sufficient wash-out time has not occurred due to the schedule or PK properties of an agent, a longer wash-out period will be required, as agreed by the principal investigator. 5. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. 6. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable. 7. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of study treatment. 8. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection (except HBV infection or HCV infection), symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent 9. History of another primary malignancy except for conditions listed in the protocol. 10. History of leptomeningeal carcinomatosis 11. Brain metastases or spinal cord compression. Patients with suspected brain metastases at screening should have an MRI (preferred) or CT each preferably with IV contrast of the brain prior to study entry 12. History of active primary immunodeficiency 13. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice) 14. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of the trial treatment. 15. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (RECIST 1.1) | From date of randomization until the date of first documented confirmed response rate by RECIST 1.1, assessed up to 60 months | To assess the objective response rate (RECIST 1.1) of HAIC-PF + lipiodol embolization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate (mRECIST) | From date of randomization until the date of first documented confirmed response rate by mRECIST, assessed up to 60 months | To assess the objective response rate (modified RECIST) of HAIC-PF + lipiodol embolization |
| Liver specific objective response rate (RECIST 1.1 & modified RECIST) | From date of randomization until the date of first documented liver specific confirmed response rate by RECIST 1.1 & mRECIST, assessed up to 60 months | To assess the liver specific objective response rate (RECIST 1.1 & modified RECIST) of HAIC-PF + lipiodol embolization. |
| Progression-free survival (RECIST 1.1 and modified RECIST) | From date of randomization until the date of first documented progression (RECIST 1.1 or mRECIST) or date of death from any cause, whichever came first, assessed up to 60months | To assess the progression-free survival (RECIST 1.1 or modified RECIST) of HAIC-PF + lipiodol embolization |
| Overall survival | From date of randomization until the date of first documented date of death from any cause, whichever came first, assessed up to 60 months | To assess the overall survival of HAIC-PF + lipiodol embolization |
| Incidence of treatment-emergent adverse events [safety and tolerability] | From date of randomization until 3 months after the end-of-trial, assessed up to 60months | To assess the incidence of treatment-emergent adverse events of HAIC-PF + lipiodol embolization by reporting number of participants with treatment-related adverse events as assessed by CTCAE v5.0 |
Countries
Taiwan
Contacts
Primary ContactTsung-Hao Liu, MD
Outcome results
None listed